The Journal of Hip Surgery 2022; 06(01): 008-014
DOI: 10.1055/s-0041-1739456
Original Article

Postoperative Doxycycline Did Not Improve Early Postoperative Outcomes in Hip Arthroscopy Patients: A Retrospective Cohort Study

Zeeshan M. Akhtar
1   Department of Orthopaedics, University of Kentucky, Lexington, Kentucky
,
Emily R. Hunt
1   Department of Orthopaedics, University of Kentucky, Lexington, Kentucky
,
Brooks N. Platt
1   Department of Orthopaedics, University of Kentucky, Lexington, Kentucky
,
Alex L. Turner
1   Department of Orthopaedics, University of Kentucky, Lexington, Kentucky
,
Cale A. Jacobs
2   Department of Orthopaedic Surgery & Sports Medicine, University of Kentucky Medical Center, Lexington, Kentucky
,
Austin V. Stone
1   Department of Orthopaedics, University of Kentucky, Lexington, Kentucky
,
Stephen T. Duncan
1   Department of Orthopaedics, University of Kentucky, Lexington, Kentucky
› Author Affiliations

Abstract

Doxycycline has been shown to reduce fibroblast activity in the treatment of multiple pathologies, and was utilized as part of the postoperative medication protocol to help prevent adhesions from developing after hip arthroscopy. The purpose of this study was to compare early postoperative pain outcomes between consecutive case series of femoroacetabular impingement syndrome (FAIS) patients treated with or without a 7-day postoperative course of doxycycline following hip arthroscopy. We hypothesized that the doxycycline-treated group would have superior patient-reported outcomes at 6 weeks, and the effect would be more pronounced for patients with low preoperative mental health scores.

Our institutional review board–approved prospective outcomes registry was queried for patients who had undergone arthroscopic femoral osteochondroplasty and/or labral repair or reconstruction secondary to FAIS performed by a single, fellowship-trained surgeon. A 7-day postoperative course of doxycycline was initiated in 2018. Six-week postoperative Hip Disability and Osteoarthritis Outcome Score (HOOS) global (HOOSglobal) and International Hip Outcome Tool (iHOT) scores were compared between the consecutive series treated with versus without doxycycline. Additional subgroup analysis was performed on patients with low preoperative Veterans RAND 12-Item Health Survey (VR-12) mental component scores to determine possible additional benefit of postoperative doxycycline in this group.

A total of 134 patients (98 female, 36 male, age = 36.2 ± 13.4 years, body mass index [BMI] = 27.2 ± 5 kg/m2) were identified between 2013 and 2020. There were no differences between the control (n = 84) and doxycycline group (n = 50) in age, sex, or BMI. Postoperative HOOSglobal scores (control = 58.5 ± 13.1, doxycycline = 58.7 ± 14.7, p = 0.96) and iHOT scores (control = 54.4 ± 22.2, doxycycline = 52.3 ± 24.8, p = 0.61) did not differ between groups. The subset of 83 patients with low preoperative mental scores showed no differences in HOOSglobal (control = 51.6 ± 13.3, doxycycline = 57.3 ± 7.4, p = 0.12) or iHOT scores (control = 45.5 ± 20.3, doxycycline = 53.6 ± 23.1, p = 0.250).

Our results do not support the hypothesis that postoperative doxycycline leads to significant improvement in early postoperative pain scores or functional outcomes in patients undergoing hip arthroscopy for FAIS.

Data Availability

IRB protocol# 47170, approved August 19, 2020.




Publication History

Received: 24 April 2021

Accepted: 06 October 2021

Article published online:
18 November 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA